Monitor for future clinical data readouts from this and other investigator-sponsored studies, which could support regulatory discussions for label expansion and potentially increase the addressable market for PEDMARK beyond pediatric patients.
Price Chart
Executive Summary
Fennec Pharmaceuticals announced the initiation of an investigator-sponsored Phase I/II study by the University of Arizona Cancer Center to evaluate PEDMARK in adolescent, young adult, and adult patients with head and neck and testicular cancers receiving cisplatin. This expands real-world validation efforts beyond the drug's current pediatric indication.
Key Facts
- University of Arizona Cancer Center is initiating a Phase I/II open-label trial of PEDMARK (sodium thiosulfate) as an otoprotectant in adults receiving cisplatin chemotherapy
- Study focuses on adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers
- PEDMARK is currently FDA-approved only for pediatric patients with localized, non-metastatic solid tumors
- This is the third institution-led study announced by Fennec in recent months, following studies at Tampa General Hospital and City of Hope
- The announcement is part of Fennec's strategy to generate real-world evidence to support potential future label expansion
Financial Impact
No immediate financial impact disclosed; potential long-term revenue expansion if label is broadened to AYA and adult populations
Risk Factors
- Clinical trial may not demonstrate efficacy in adult populations
- Regulatory authorities may not accept data from investigator-sponsored trials for label expansion
- Competition from other otoprotectants or treatment approaches
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-040414 |
| Document: fencf-20260407xex99d1.htm | 0001104659-26-040414 |
| Document: 0001104659-26-040414-index-headers.html | 0001104659-26-040414 |
| Document: 0001104659-26-040414-index.html | 0001104659-26-040414 |
| Document: 0001104659-26-040414.txt | 0001104659-26-040414 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G/A | $10.27 | awaiting T+60 | — | $10.15 (−1.17%) |
Aug 31, 2026 7w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.15 (−15.63%) |
Aug 31, 2026 7w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.15 (−15.63%) |
Aug 11, 2026 10w ago | Press Release | $12.78 | awaiting T+60 | — | $10.15 (−20.58%) |
Jun 15, 2026 19w ago | Press Release | $9.19 $11.65 | ▲ +26.77% | ▲ +25.77% | $10.15 (+10.45%) |
May 22, 2026 22w ago | 8-K | $9.89 $11.87 | ▲ +20.02% | ▲ +17.30% | $10.15 (+2.63%) |
May 18, 2026 22w ago | 8-K | $9.76 $12.06 | ▲ +23.57% | ▲ +17.28% | $10.15 (+4.00%) |
May 14, 2026 23w ago | Press Release | $9.24 $10.94 | ▲ +18.40% | ▲ +14.81% | $10.15 (+9.85%) |
May 7, 2026 24w ago | Press Release | $6.90 $9.59 | ▲ +38.99% | ▲ +35.15% | $10.15 (+47.10%) |
Apr 28, 2026 25w ago | 8-K | $6.26 $9.99 | ▲ +59.58% | ▲ +55.47% | $10.15 (+62.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers